Publication date: Jun 06, 2019
Professor Michael P Brown presents on GD2-CAR-T cell therapy for metastatic uveal melanoma at the 1st Australasian Ocular Melanoma Summit, held at the Garvan Institute of Medical Research in Sydney on May 3rd-4th, 2019.
The Australasian Ocular Melanoma Alliance (AOMA) presents the 1st Australasian Ocular Melanoma Summit. The AOMA group was founded in late 2017 by Melanoma and Skin Cancer Trials Ltd to support clinicians and researchers from all disciplines to develop, seek funding for, and collaborate on clinical trials in ocular melanoma.
Follow us at;
Australasian Ocular Melanoma Alliance – @AOMA_MASC
Melanoma and Skin Cancer Trials – @MASC_Trials
For more information contact us at firstname.lastname@example.org
The event was sponsored/supported by;
Melanoma and Skin Cancer Trials Limited, The Garvan Institute of Medical Research and Kinghorn Cancer Centre, Melanoma Institute Australia, The Save Sight Institute, SydPath and Cancer Australia.
|Clinical Trials||Uveal melanoma|
|Michael Brown||Clinical medicine|
- Meta-Analysis in Metastatic Uveal Melanoma to Determine Progression-Free and Overall Survival Benchmarks: an International Rare Cancers Initiative (IRCI) Ocular Melanoma study.
- Provectus Announces Updated Results from Phase 1B Trial of PV-10 in Combination with KEYTRUDA® for Treatment of Advanced Melanoma at ASCO 2019
- New Biomarker Research Builds Further Understanding of Tebentafusp (IMCgp100) Mechanism of Action, Link to Clinical Activity in Advanced Melanoma
- Unique Populations Science Panel: 2019 CURE OM Symposium